Jane Street
AVBP icon

Jane Street’s ArriVent BioPharma AVBP Stock Holding History

Jane Street’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,658
Closed -$521K – 13364
2026
Q1 		$407K Sell
17,658
-85,597
-83% -$1.93M ﹤0.01% 8523
2025
Q4 		$2.08M Buy
+103,255
New +$2.15M ﹤0.01% 4742
2024
Q4 		– Sell
-10,626
Closed -$250K – 10784
2024
Q3 		$250K Sell
10,626
-4,707
-31% -$107K ﹤0.01% 8325
2024
Q2 		$284K Sell
15,333
-21,626
-59% -$386K ﹤0.01% 7881
2024
Q1 		$660K Buy
+36,959
New +$745K ﹤0.01% 6169

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's AVBP Position: Q2 2026 in Review

Jane Street sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 17,658 shares — an estimated $521K sold.

Jane Street first reported a position in AVBP in Q1 2024 and held it in 5 quarters. The position peaked at $2.08M in Q4 2025. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Jane Street reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 17,658 ArriVent BioPharma shares in Q2 2026, an estimated $521K.
  • Jane Street first reported a position in ArriVent BioPharma in Q1 2024 and held it in 5 quarters.
  • Jane Street's ArriVent BioPharma position peaked at $2.08M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.